Latest Factor VIII Stories
KING OF PRUSSIA, Pa., July 18, 2011 /PRNewswire/ -- CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII (FVIII) replacement medication to patients through the World Federation of Hemophilia (WFH).
KING OF PRUSSIA, Pa., May 31, 2011 /PRNewswire/ -- CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
KING OF PRUSSIA, Pa., May 19, 2011 /PRNewswire/ -- Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011.
MONTVILLE, N.J., and MONTREAL, April 28, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia (WFH) are announcing a three-year extension of Bayer's sponsorship agreement with WFH.
WAYNE, N.J., April 25, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that the U.S.
WAYNE, N.J., April 14, 2011 /PRNewswire/ -- To help raise money and awareness for bleeding disorders, Bayer is launching the 2011 Bayer Virtual Walk for Hemophilia, the first interactive program of its kind in support of people with hemophilia.
BARCELONA, Spain, March 4, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it received approval from the US Food and Drug Administration (FDA) for revised labeling for AlphanateÂ® Antihemophilic Factor/von Willebrand Factor Complex (Human) indicating that certain manufacturing steps have been shown to reduce the infectivity of a experimental TSE agent that is a model for variant Creutzfeldt Jakob...
KING OF PRUSSIA, Pa. and MONTREAL, Feb.
GENEVA, Feb. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.
NES-ZIONA, Israel, Feb. 2, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice.
- One who brings meat to the table; hence, in some countries, the official title of the grand master or steward of the king's or a nobleman's household.